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KDIGO (Kidney Disease: Improving Global Outcomes) is an international nonproﬁt organization devoted to “improve the care
and outcomes of kidney disease patients worldwide through promoting coordination, collaboration, and integration of initiatives
to develop and implement clinical practice guidelines.” The mineral and bone disorder (MBD) in patients with chronic kidney
disease (CKD) has been the ﬁrst area of interest of KDIGO international initiative. KDIGO guidelines on CKD-MBD were
published in 2009 with the intent to modify the previous KDOQI guidelines that had failed to consistently change the global
outcomeof CKD patients. After the publication of KDOQIguidelines for bone metabolism and disease in 2003,a large number of
observational data emerged in literature linking disordered mineral metabolism with adverse clinical outcomes. Notwithstanding
this large body of observational data, a paucity of evidence from high-quality clinical trials was available for the development
of KDIGO guidelines. Herein, a summary will be provided of the most important ﬁndings of KDIGO guidelines regarding the
diagnostic workup and clinical monitoringof CKD-MBD patients.
1.Introduction
The nonproﬁt foundation KDIGO(KidneyDisease: Improv-
ing Global Outcomes) was established in 2003 with the
aim to improve outcomes in CKD patients through the
optimization of care.
The mineral and bone disorder (MBD) in CKD has
been the ﬁrst area of interest of the KDIGO international
initiative. A KDIGO position statement published in 2006
deﬁned CKD-MBD disease as due to either one or a combi-
nation of the following clinical situations: (a) abnormalities
of calcium, phosphorus, parathyroid hormone (PTH), or
vitamin D metabolism; (b) abnormalities in bone turnover,
mineralization, volume, linear growth, or strength; (c)
vascular or other soft tissue calciﬁcation [1]. The term renal
osteodystrophy was limited to the diagnosis of alterations in
bone morphology and their histomorphometric quantiﬁca-
tionbybonebiopsy.Withregardtothevolumeandqualityof
evidence,aKDIGOWorkGroupofinternational expertsand
an Evidence Review Team (ERT) were set up to collaborate
for the development of a set of new guidelines for the care of
adults and children with CKD stages 3–5 and for patients on
chronic dialysis therapy or with a kidney transplant. To this
purpose,theendpointsofdirect importancetopatientswere
identiﬁedasfollows: mortality,cardiovascular disease events,
fractures, hospitalisation, and quality of life. Intermediate
and biochemical end points were also identiﬁed: vascular
calciﬁcation, bone mineral density and bone biopsy, and
circulating levels of PTH, calcium, phosphorus, and alkaline
phosphatases. Only the randomised controlled trials (RCTs)
of at least a 6-month duration with a sample size of more
than 50 patients were takeninto considerationfor systematic
review. An exception was made for studies involving bone
biopsy, in which smaller sample sizes were accepted. For the
development of KDIGO guidelines, evidence from literature
was graded according to the Grading of Recommendations2 International Journal of Nephrology























Assessment, Development, and Evaluation system (GRADE)
[2, 3]. The strength of evidence was graded “strong” (level
1) and “weak” (level 2), indicating recommendation and
suggestion, respectively, the quality of evidence was distin-
guished into A (high), B (moderate), C (low), and D (very
low). KDIGO guidelines for CKD-MBD were published in
August 2009, and they established targets and strategies for
biochemicalboneandvascularcomponentsofthissyndrome
[4]. Unfortunately, due to the limited volume of available
high-quality evidence found in the literature by the ERT, in
the guidelines, the suggestions were largely more frequent
than the recommendations. KDIGO appeared extremely
cautious mainly in the ﬁeld of therapeutic interventions due
to the almost complete lack of clinical trial data supporting
speciﬁc therapeutic strategies. According to the KDIGO
guidelines, the diagnostic workup of CKD-MBD should
include both the evaluation of biochemical abnormalities
and of bone and vascular involvement in a CKD patient.
2.Biochemical Abnormalities
The KDOQI guidelines recommend that laboratory moni-
toring should begin in CKDstage 3 in adults (1C)and earlier
at CKDstage 2 in children (2D). Table 1 shows the frequency
of monitoring of the main laboratory parameters for CKD-
MBD in adults. The frequency of measurements can be
increased in CKD patients receiving treatments for CKD-
MBD or in those in which biochemical abnormalities have
been identiﬁed. Target levels for biochemical parameters
are illustrated in Table 2, together with those indicated
previously by the KDOQI guidelines [5].
2.1. Calcemia and Phosphatemia. According to the KDIGO
guidelines, the target for calcium and phosphorus is to
maintain circulating levels at the normal laboratory range
(2C and 2D, resp.) at all stages of CKD. In particular, in
CKD stage 5, phosphorus levels should not be simply equal
to the upper phosphorus level of 5.5mg/dL, as suggested
by KDOQI guidelines, but should be lowered as much
as possible toward the laboratory limit, which is lower
than 5.5mg/dL. Importantly, some observational studies of
patients with normal renal function have shown that higher
levels of serum phosphorus, even within the normal range,
are associated with increased cardiovascular morbility and
mortality [6].Unfortunately, thereare no prospective studies
that have speciﬁcally identiﬁed the inﬂection point at which
the increase in phosphorus becomes signiﬁcantly associated
with reduced survival and increased cardiovascular morbid-
ity and mortality in patients at all stages of CKD. However,
there is an increasing awareness of the dangerousness of
hyperphosphatemia which is accompanied by the current
tendency to maintain circulating phosphorus levels as low as
possible, in the absence of conditions of malnutrition.
Like phosphorus, calcium levels should also be main-
tained within the normal laboratory range. It has been
observed that calcium levels >9.5mg/dL (>2.38mmol/L)
or even higher are associated with increased mortality
in CKD patients [7–11]. Conversely, there is not much
evidence of an association between low levels of calcium
and mortality, and data of literature are controversial [8].
In recent observational studies, however, low serum calcium
levels were associated with increased mortality in time-
varying analyses and in combination with higher serum
phosphorus(>3.5mg/dL)and PTH levels(>150pg/mL) [12,
13]. On the other hand, there are two aspects to consider.
The ﬁrst aspect is methodological, and it concerns the use
of calcium corrected for albumin by means of formulas,
which is very common in scientiﬁc literature. Recent studies
have demonstrated that, considering ionized calcium as gold
standard, the “corrected calcium” formula does not oﬀerany
superiority over total calcium for diagnosis [14]. For this
reason, the KDIGO Work Group felt that both corrected
calcium measurements and total calcium should continue to
be used if they are part of the routine clinical practice. The
second aspect is the evaluation of the calcium-phosphorus
product. The eﬀectiveness of this mathematical parameter
in the clinical practice has recently been objected when
compared with the evaluation of calcium and phosphorus
alone. Welcoming these objections, KDIGO guidelines no
longer recommend the use of this parameter in the clinical
practice or give any target to achieve.
2.2. Parathyroid Hormone. At present, the use of “second-
generation” PTH assays, which are widely available, is
still highly recommended in the clinical practice by the
Work Group, also in consideration of the fact that “third-
generation” PTH assays have not been shown convinc-
ingly to improve the predictive value for the diagnosis of
underlying bone disease. Second-generation assays detect
not only the entire 1–84PTH molecule, but also large
fragments 7–84 whose concentration increases in CKD [15].
Third-generation methods detect only the entire 1–84PTH
molecule.Thecombineduseofsecond-andthird-generation
assays allows measuring the 1–84PTH/7–84 ratio. In some
observational studies, this ratio has provedto be a signiﬁcant
predictor of bone disease and mortality [16]. However,
these data were not a suﬃcient basis for recommending
the preferential use of third-generation methods, which are
also not yet widely available. The Work Group aﬃrms that
PTH target levels for patients with CKD stages 3–5 not
on dialysis are still unknown; for this reason, it was found
reasonable to suggest that in patients not yet on dialysis as
well as in those with levels of intact PTH above the upperInternational Journal of Nephrology 3
Table 2: KDIGO guideline for CKD-MBD: laboratory target range.
CKD stage (mL/min) PTH target
KDOQI KDIGO
3 (59–30) 25–70




In the range of 2–9 times
the upper reference limit
for the assay without
marked changes over time




In the reference range 4 (29–15)
5( <15)
3.5–5.5
5D (dialysis) Toward the reference range
CKD stage (mL/min) Calcium target
KDOQI KDIGO
3 (59–30) In the reference
range




normal limit (2C) of the assay, calcium and phosphorus
abnormalities be ﬁrst evaluated and eventually treated. In
fact, moderately elevated levels of PTH at this stage might
express an adaptive mechanism which is still eﬃcacious
and requires only interventions on the causative factors
represented by bone mineral disorders.
As for dialysis patients with CKD stage 5, instead, the
Work Group suggests that only those patients for which
the following double requirement of PTH levels is satisﬁed,
be considered within the PTH target: PTH levels in the
range of approximately two to nine times the upper normal
limit for the assay (2C) and circulating levels remaining
stable over the time. Actually, many observational studies
have investigated the relationship between the circulating
levels of PTH and adverse outcome, but the results obtained
were often divergent, especially for low levels of PTH. In
a large observational study, only intact PTH levels higher
than 600pg/mL were associated with an increased mortality
risk [7]. Even more controversial is the relationship between
mortality and low levels of PTH [17, 18]. It is possible that
some interactive factors have a role in this relationship, such
as comorbidities, which aﬀect a great number of CKD and
ESRD patients [18]. It is important to observe that in the
KDIGO guidelines PTH targets have been anchored to the
speciﬁc method applied. As a matter of fact, many diﬀerent
results from methods of the same generation have been
reported [19]. This can be misleading in the application
of guidelines in which target values refer to assays that are
diﬀerent from those used in the clinical practice. KDOQI
guidelines suggested to maintain PTH levels between 150
and 300pg/mL in CKD stage 5 patients, but this target
range was based on studies where PTH was assayed with
second-generation intact PTH Allegro Nichols IRMA, but
thatassay wasnolongercommerciallyavailableafter KDOQI
guidelines release. Referring target levels of PTH to the
speciﬁc method applied is one of the great merits of
KDIGO guidelines. Unfortunately, there is no information
in these guidelines on the collection timing in relation to
the frequency of hemodialysis and pulsatile PTH secretion,
which is an area that has been little investigated in CKD and
ESRD patients [20, 21].
2.3. Vitamin D. CKD patients are characterized not only
by a deﬁcit in renal 1 alpha hydroxylase, which causes low
levels of 1,25 dihydroxyvitamin D (1.25VD), but also by
a high-frequency deﬁcit in circulating 25-hydroxyvitamin
D[ 22–24]. The circulating levels of 25VD are present in
multiplequantitiescomparedtothoseof1,25VD,and25VD
represents the nutritional form of a vitamin acting like
an hormone. In fact, in addition to its established role in
mineral homeostasis, vitamin D also seems to be crucially
involved in other functions related to cellular response to
environmental stimuli [25–27]. In particular, 25VD seems
to be hydroxylated by one extrarenal 1 alpha hydroxylase in
many cells, even extrarenal cells. If activated locally in these
cells, vitamin D is believed to be able to unblock genetic
backgrounds and regulate important cell functions. These
functions, called autocrine, could be helpful to explain the
nontraditional eﬀects of this hormone, in other words those
eﬀects which are not directly associated to its regulatory
role in mineral metabolism. These nontraditional eﬀects of
vitamin D aﬀect various ﬁelds related to pathology, from
oncology to immunopathology and cardiovascular pathol-
ogy; moreover, they seem to have a role in the protection4 International Journal of Nephrology
of survival even in non-CKD patients [27, 28]. In patients
with stages 3–5D, the KDIGO guidelines suggest measuring
circulating levels of 25VD and repeating testing at intervals
determinedby the baseline valuesobtained(2C).However, it
has also been emphasized that testing methods for 25VD are
not yet standardized, and deﬁnitions of “insuﬃciency” and
“deﬁciency” need to be further validated in CKD patients.
These deﬁnitions should also take into account the season
and the geographical area where the assay is performed,
as these parameters could inﬂuence the exposure and the
consequent production of vitamin D.
2.4.Alkaline Phosphatases. Thefrequencyofmeasurementof
alkaline phosphatases is very similar to that of PTH and can
provide additional information on bone turnover. In fact,
as some comparative histological studies have demonstrated,
PTH alone is not a good predictor of bone mineral disease
with high and low turnover, except for respectively very high
or very low values [29]. The Work Group believes that total
alkaline phosphatases can contribute to correctly evaluating
the status of skeletal metabolism, even in the presence of
treatments interfering with bone turnover. However, in the
presence of very high levels of total alkaline phosphatases,
concomitant conditions such as hepatopathy and cholestasis
must be excluded. Bone alkaline phosphatases can help to
resolve interpretative doubts about the extra bone origin of
alkaline phosphatases.
The importance of measuring alkaline phosphatases
is emphasized by recent studies showing the association
between total alkaline phosphatase levels and mortality in
CKD and ESRD patients [30, 31]. It is recommended that
for everylaboratory test, all necessary information about the
actual assay method in use be obtained by clinicians, who
are also recommendedtobase therapeuticdecisionsontrend
rather than on a single laboratory value.
The same laboratory tests and timing of monitoring
are also applicable to transplanted patients (CKD stages 1–
5T), even to patients at the period immediately after kidney
transplant the KDIGO guidelines recommend measuring
serum calcium and phosphorus at least weekly, until these
parameters have become stabilized.
3.Vascularand Bone Abnormalities
There is evidence in literature of the existence of a relation-
ship between bone and vessels predisposing to the formation
of vascular and soft tissue calciﬁcations in CKD-MBD
patients and in those with abnormal mineral metabolism
[32]. Hypercalcemia and, above all, hyperphosphatemia may
be the main responsible factors. Hyperphosphatemia is able
to activate a sodium-phosphate cotransporter, Pit-1. This
cotransporter causes theincrease in intracellular phosphorus
concentrationinvascularsmooth musclecells, thusinducing
an increase in the production of the core-binding factor
alpha-1 [33], which is a transcription factor for osteoblastic
diﬀerentiation of smooth muscle cells triggering an active
vascular ossiﬁcation process [34]. Hyperphosphatemia is
associated with progressive coronary calciﬁcation in CKD
patients [35]. In these patients, coronary and noncoronary
vascular calciﬁcations are independent predictors of survival
[36]. Vascular stiﬀness is considered to be the main cause of
elevated mortality in patients with strong vascular calciﬁca-
tion. On the basis of all these statements, KDIGO guidelines
include the study of vascular calciﬁcations and bone health
in the diagnosis of CKD-MBD.
Quantitative evaluation of coronary artery calciﬁcation
by electron beam computed tomography (EBCT) or by mul-
tislice computed tomography (MSCT) has been frequently
used for research purposes, but it is still uncommon. For
this reason, KDIGO guidelines suggest the use of other more
easily available techniques, such as lateral abdominal radio-
graph for quantiﬁcation of abdominal aortic calciﬁcations at
level L1–L4 (Kauppila method) [37], and echocardiogram
for detection of valvular calciﬁcations. The KDIGO Work
Group also suggests that CKD-MBD patients with high
presence of vascular calciﬁcations should be considered at
the highest cardiovascular risk in the clinical management
of this pathology. Bone biopsy is the gold standard for the
diagnosis of bone disease, and it should be limited to some
speciﬁc settings in CKD patients: unexplained fractures, per-
sistent bone pain, unexplained hypercalcemia, unexplained
hypophosphatemia, possible aluminum toxicity,and priorto
therapy with bisphosphonates. The detection of bone dis-
eases through bone biopsy is possible through the evaluation
of three parameters: turnover, measured as bone-formation
rate, mineralization, measured as unmineralized osteoid,
and bone volume (TMV classiﬁcation). Osteitis ﬁbrosa,
characterized by high bone turnover, normal mineralization
and increased bone volume, is still the most frequent form
of uremic osteodystrophy in CKD patients not on dialysis
and in hemodialysis patients, although in these patients it
is progressively becoming less frequent compared to those
on peritoneal dialysis. Adynamic bone disease, characterized
by low bone turnover, normal mineralization, and low
b o n ev o l u m e ,i sv e r yc o m m o ni np a t i e n t so np e r i t o n e a l
dialysis and is becoming progressively more frequent also
in CKD patients not on dialysis and in those on chronic
hemodialysis. Osteomalacia, characterized by reduced bone
turnover, abnormal mineralization, and little or unchanged
bone volume, is not very frequent (<10%) in patients
with CKD stages 3–5D. Mixed renal osteodystrophy, mainly
aﬀecting patients on chronic hemodialysis, is similar to
osteitis ﬁbrosa in terms of bone turnover and to osteoma-
lacia for mineralization and bone turnover. Finally, renal
osteodystrophy with mild lesions, mainly aﬀecting patients
on peritoneal dialysis, has lesions similar to those of osteitis
ﬁbrosa, but with lesser degree of changes in turnover and
bone volume.
The KDIGOguidelines emphasize that the most accurate
tools for the diagnosis of renal osteodystrophy are bone
biopsy and TMV classiﬁcation. Other indirect methods
are less accurate, as in the case of BMD, whose ability
to predict fracture risk in patients with CKD stages 3–
5a si td o e si nt h eg e n e r a lp o p u l a t i o ni sn o tc o n ﬁ r m e d .
BMD cannot certainly distinguish between diﬀerent types
of renal osteodystrophy. As mentioned above, measurements
of circulating PTH do not provide adequate diagnosticInternational Journal of Nephrology 5
information on the type of bone disease, except for very
high or very low levels. Not even the laboratory aid of
bonealkalinephosphatasesandbiochemicalmarkers ofbone
turnoverincreasessuﬃcientlythepredictivevalueofPTHfor
the underlying bone disease. Additionally, the measurement
of bone mineral density (BMD) and biochemical markers of
bone turnover should not be performed routinely in CKD
patients stages 3–5. However, postmenopausal or age-related
osteoporosis can be detected by BMD at earlier stages of
CKD (until early stage 3). In later stages and in the presence
of CKD-MBD, the underlying bone lesion should always
be deﬁned as renal osteodystrophy and not osteoporosis;
the gold standard diagnosis is bone biopsy, as mentioned
above.Intransplanted patientswithanestimated glomerular
ﬁltration rate greater than approximately 30mL/min per
1.73m2, measurement of BMD is suggested in the ﬁrst 3
months after kidney transplant.
Bone fragility and especially vertebral and hip fractures
are two of the main characteristics of renal osteodystrophy
and are caused by abnormal bone quality [38]. These
fractures are often unknown or diﬃcult to detect; thus, a
careful radiographic investigation is necessary given their
important association with increased mortality and vascular
calciﬁcation [39]. The encouragement to expand the investi-
gation of bone fractures for diagnosis in CKD-MBDpatients
is clearly evident in the KDIGO guidelines.
4.Conclusions
KDOQI guidelines attribute a syndromic dimension to
the abnormalities in the parathyroid-bone axis, which is
responsible for worsening chronic renal failure. Alterations
in mineral metabolism represent the core of this syndrome,
and the KDOQI guidelines strongly recommend their thera-
peuticmonitoringasthepivotalaspectforthecorrectclinical
management of the disease at all CKD stages. This core is
surrounded by parathyroid, bone, and vascular abnormali-
ties. A correct diagnostic workup for CKD patients can no
longer be limited to periodic laboratory measurements of
circulatinglevelsofPTH,calcium,andphosphorus.Itshould
also include the measurement of total alkaline phosphatase
andthedetectionof deﬁcitofthenutritional form ofvitamin
D. Together with this, the search for bone fractures as well
as for vascular calciﬁcations and, in speciﬁc cases, the char-
acterization of osteodystrophy through bone biopsy should
also be considered. This extension of the diagnostic workup
of CKD-MBD is aimed at the prognostic determination of
the CKD stage in the patient, with consequences in the
clinical management of the disease. As a matter of fact,
patients with signiﬁcant bone and/or vascular involvement
are to be considered at higher risk and need to be treated. In
these patients, any concomitant cardiovascular risk factors,
both traditional and uremia related, if subject to possible
changes, will require a particularly intensive treatment.
However, KDIGO is extremely cautious in recommending
such interventions, due to the almost complete lack of
clinical trial data supporting speciﬁc strategies.
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